세계 스마트 인슐린 펜 시장 규모는 2023년 5,140만 달러, 2031년 1억 2,909만 달러로 2024-2031년의 예측 기간 동안 12.2%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 당뇨병 유병률 증가, 혈당 관리 개선, 환자 편의성 향상, 지속적인 기술 발전, 원격 의료에 대한 관심 증가, 인식 제고, 투약 실수 위험 최소화, 잠재적 의료 비용 절감 등 다양한 요인이 세계 스마트 인슐린 펜 시장을 주도하고 있습니다.
세계 스마트 인슐린 펜 시장은 당뇨병 관리에 있어 큰 도약을 의미합니다. 이 획기적인 장치는 당뇨병 환자의 인슐린 투여 과정에 혁명을 일으켜 정확성, 편의성, 데이터 기반 통찰력을 향상시켜 전반적인 웰빙과 삶의 질을 개선할 수 있도록 돕습니다. 전 세계적으로 당뇨병이 유행하고 효율적이고 사용하기 쉬운 당뇨병 관리 도구에 대한 수요가 증가하면서 세계 스마트 인슐린 펜 시장의 성장을 견인하고 있습니다. 의료 제공업체와 환자 모두 인슐린 요법을 개선하고 보다 효과적인 혈당 조절과 당뇨병으로 인한 장기적인 합병증 감소로 이어질 수 있는 스마트 인슐린 펜의 잠재력을 인정하고 있습니다.
세계 스마트 인슐린 펜 시장은 제조업체들의 기술 발전과 점점 더 정교해지는 기능 및 연결성 옵션의 도입으로 지속적인 성장세를 보이고 있습니다. 스마트 인슐린 펜은 자동화된 정확한 용량 계산을 용이하게 하는 기술을 갖추고 있어 인슐린 투여 중 인적 오류의 가능성을 줄여줍니다. 이 장치는 스마트폰 앱과 무선 연결을 통해 인슐린 투여 기록, 혈당 및 기타 중요한 데이터를 추적할 수 있습니다. 이는 당뇨병 관리 개선과 만성 질환을 앓고 있는 개인의 독립성을 향상시킬 수 있는 유망한 전망을 제시합니다.
당뇨병 모니터링과 관리에 스마트한 방법을 사용하는 것에 대한 인식이 높아지면서 전 세계 스마트 인슐린 펜 시장이 크게 성장하고 있습니다. 당뇨병 치료는 전통적인 대면 진료에서 화상 진료와 같은 동기식 원격 진료 방식으로 전환되고 있으며, 주로 시장 신생 기업이 제공하는 비동기식 디지털 의료 서비스도 증가하고 있습니다. 미국에서는 지난 수십년동안 인슐린 펜의 사용이 꾸준히 증가하고 있으며, 1형 당뇨병(T1D)과 2형 당뇨병(T2D) 환자들에게 선호되는 인슐린 투여 방법이 되고 있습니다. 인슐린 펜은 현재 상업 보험 가입자 사이에서 시장을 독점하고 있습니다. 환자들이 인슐린 펜을 선택하는 이유는 인슐린 바이알이나 주사기 방식에 비해 만족도가 높고 사용하기 쉽기 때문입니다. 인슐린 펜은 우수한 투약 정확도를 제공하여 인슐린 순응도를 향상시킬 수 있습니다. 또한, 인슐린 펜을 사용하면 HbA1c 수치를 낮추고 고혈당을 최소화하여 혈당 조절이 더 잘 되는 것으로 나타났습니다. 초기 비용이 높지만 인슐린 펜은 총 의료비 절감으로 이어져 입원, 당뇨병 관련 입원 및 고혈당으로 인한 의료 이용 감소로 이어집니다.
기술 혁신은 전 세계 스마트 인슐린 펜 시장의 판도를 바꾸어 놓았습니다. 이러한 개발에는 정확한 용량 계산, 즉각적인 스마트폰 데이터 통합, 사용자 친화적인 인터페이스 등이 포함됩니다. 스마트 인슐린 펜의 진화는 사람들에게 효율적인 건강 관리 수단을 제공하여 궁극적으로 웰빙과 삶의 질을 향상시킬 수 있습니다. 예를 들어, 2023년 3월 자동 인슐린 전달의 선구자 디아벨루프(Diabeloop)는 저명한 세계 의료 기업 노보 노디스크(Novo Nordisk)와의 제휴를 발표했습니다. 양사의 노력은 커넥티드 인슐린 펜을 통합한 상호운용성 전략을 추진하는 데 초점을 맞추었습니다. 이번 계약은 Diabeloop의 자가 학습형 MDI(Multiple Daily Injections) 치료 알고리즘인 DBL-4pen(TM)과 Novo Nordisk의 NovoPen(R)6 및 NovoPen Echo(R) Plus와 같은 재사용 가능한 커넥티드 인슐린 펜의 통합을 포함합니다.
이 보고서는 세계 스마트 인슐린 펜 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 및 전망 등의 정보를 제공합니다.
Global Smart Insulin Pens Market size was valued at USD 51.4 million in 2023, expected to reach USD 129.09 million in 2031 with a CAGR of 12.2% for the forecast period between 2024 and 2031F. Numerous factors are propelling the global smart insulin pens market forward, including the increasing prevalence of diabetes, better management of glycaemic levels, increased patient convenience, ongoing technological progress, a heightened emphasis on telehealth, growing awareness, minimized medication error risk, and potential healthcare cost reductions.
The global smart insulin pens market signifies a significant leap forward in diabetes management. These groundbreaking devices have revolutionized the insulin administration process for people with diabetes, providing them with improved accuracy, convenience, and data-driven insights to improve their overall well-being and quality of life. The escalating global diabetes prevalence and the growing need for efficient and user-friendly diabetes management tools have fuelled the expansion of the global smart insulin pens market. Both healthcare providers and patients are increasingly acknowledging the potential of these devices to improve insulin therapy, leading to more effective glycaemic control and a reduction in the long-term complications associated with diabetes.
With the evolution of technology and the introduction of increasingly sophisticated features and connectivity choices by manufacturers, the global smart insulin pens market is positioned for ongoing growth. Smart insulin pens are furnished with technology that facilitates automated and precise dose calculations, diminishing the potential for human errors during insulin administration. These devices frequently establish wireless connections with smartphone applications, enabling users to track their insulin dosing history, blood glucose levels, and other vital data. This presents a promising outlook for improved diabetes management and increased independence for individuals with this chronic condition.
The increased awareness of using smart methods to monitor and control diabetes has led to significant growth in the global smart insulin pens market. Diabetes care is transitioning from traditional in-person office visits to synchronous telehealth methods, such as video consultations, and increasingly, asynchronous digital healthcare services, primarily provided by emerging players in the market. In the United States, the utilization of insulin pens has witnessed a consistent rise over the past few decades, becoming the preferred mode of insulin delivery for both type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. Insulin pens now dominate the market among commercially insured individuals. Patients opt for insulin pens due to their high satisfaction levels and user-friendliness compared to insulin vial and syringe methods. These pens offer superior dose accuracy, leading to improved insulin adherence. Moreover, insulin pen usage has demonstrated better glycaemic controls, reducing HbA1c levels and minimizing hyperglycemia. Despite initial higher costs, insulin pens translate into lower total healthcare expenses, resulting in fewer hospitalizations, diabetes-related admissions, and instances of hyperglycemia-associated healthcare utilization for users.
Innovations in technology have transformed the realm of the global smart insulin pens market. These developments include precise dose computations, immediate smartphone data integration, and user-friendly interfaces. The evolution of smart insulin pens provides individuals with efficient means of managing their health, ultimately resulting in enhanced well-being and a better quality of life. For example, in March 2023, Diabeloop, a trailblazer in Automated Insulin Delivery, revealed a partnership with Novo Nordisk, a prominent global healthcare firm. Their joint effort focuses on advancing an interoperability strategy incorporating connected insulin pens. The agreement involves the integration of Diabeloop's self-learning algorithm for Multiple Daily Injections (MDI) therapy, DBL-4pen™, with Novo Nordisk's connected and reusable insulin pens, including NovoPen® 6 and NovoPen Echo® Plus.
Government programs focusing on smart insulin pens are pivotal in tackling the worldwide diabetes crisis and improving the well-being of those afflicted with the condition. Governments efforts give a huge boost to global smart insulin pens market. These efforts reflect a forward-looking approach governments took to combat the increasing incidence of diabetes and the escalating need for cutting-edge solutions in diabetes care and management. On January 1, 2023, a notable development occurred as smart insulin pens were incorporated into Medicare Part D by the US government. This means that individuals enrolled in Medicare who rely on smart insulin pens will now have their expenses capped at a maximum of $35 per month for a one-month supply of each approved insulin product. This pivotal inclusion of smart insulin pens in Medicare Part D was mandated under the Affordable Care Act, commonly known as Obamacare. The ACA mandates Medicare to encompass specific categories of diabetes-related supplies, among them being insulin pens. Such initiatives have a large impact on the global smart insulin pens market.
The advent of Bluetooth-enabled smart insulin pens marks a substantial advancement in global smart insulin pens market. These cutting-edge tools amalgamate the precision inherent in conventional insulin pens with the capabilities of Bluetooth connectivity, presenting users with a cohesive and data-centric methodology for managing their insulin therapy. By facilitating immediate data transfer to smartphones and other suitable devices, these smart insulin pens empower individuals managing diabetes to meticulously monitor their insulin doses, oversee blood glucose levels, receive dose guidance, and seamlessly communicate vital health data with healthcare professionals. As an example, in December 2022, Biocorp, a French firm specializing in medical devices and drug delivery systems, unveiled its FDA 510(k) clearance to commercialize the Mallya smart medical device, designed to interface with insulin pens. Mallya, functioning as a smart sensor, seamlessly affixes to insulin pen injectors, effectively transforming them into connected devices via bluetooth.
Disposable smart insulin pens are reshaping diabetes management by merging the simplicity of one-time-use pens with state-of-the-art technology, ultimately influencing the global smart insulin pens market. These compact instruments come pre-filled with insulin and boast smart capabilities like dosage monitoring, reminders, and wireless connectivity. This enables users to administer insulin with accuracy while effortlessly overseeing their treatment progress. The disposability factor removes the necessity for cartridge swaps, streamlining insulin administration and boosting patient adherence. As an example, in November 2021, the French multinational pharmaceutical and healthcare company Sanofi and the Swiss multinational healthcare company Roche established a collaborative effort in France. They united their efforts to promote the utilization of a connected accessory designed for disposable insulin pens. Together, they will create an educational program for healthcare professionals, including physicians and retail pharmacists, focusing on the Biocorp product known as Mallya.
COVID-19 pandemic had a huge impact on the global smart insulin pens market. On one hand, the demand for smart insulin pens surged during the pandemic, primarily driven by the heightened vulnerability of people with diabetes to severe COVID-19 complications, given their increased susceptibility to respiratory infections. This elevated demand was fueled by the urgency for effective diabetes management to reduce hospitalization risks. Conversely, the pandemic disrupted the supply chain for smart insulin pens as production facilities and distribution networks faced closures and shipping challenges, leading to shortages in certain regions. However, despite these short-term setbacks, the long-term outlook for smart insulin pen sales remains positive. COVID-19 underscored the critical importance of effective diabetes management, shedding light on the role smart insulin pens can play in empowering individuals with diabetes to manage their condition proactively and remotely. This heightened awareness is expected to drive sustained growth in the smart insulin pens market.
Amidst the rapidly changing healthcare environment, marked by a strong emphasis on precision, connectivity, and patient-centric care, the global market for smart insulin pens is experiencing a multitude of partnerships and cooperative ventures. These endeavors frequently bring together a diverse array of stakeholders, including pharmaceutical firms, technology enterprises, startups, and healthcare providers, who combine their knowledge and resources with the goal of creating advanced smart insulin pens. These next-generation devices aim not only to enhance insulin delivery precision but also to offer users immediate data insights and the ability to remotely monitor their insulin therapy. In May 2021, Eli Lilly & Co., an American pharmaceutical company, took steps to ensure the compatibility of its forthcoming connected insulin pen system with various daily diabetes management platforms by entering into compatibility agreements with four global providers. These agreements encompass a range of offerings, such as glucose monitoring sensors, digital health solutions, and other resources provided by Roche, Dexcom, Glooko, and myDiabby Healthcare.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.